2 results
·
26ms
·
Sources: EU EUDAMED, US FDA
Filters
Status: Terminated
×
Cardiogenesis Corporation - Cardiogenesis Transmyocardial Laser. The device is indicated for use in the treatment of patients with angina (Canadian Cardiovascular Society Class 4) refractory to medical treatment and secondary to objectively demonstrated coronary artery atherosclerosis and with a region of the myocardium with reversible ischemia not amenable to direct coronary revascularization.
FDA Enforcement
Class II
·Terminated·Cardiogenesis Corporation·September 18, 2013
Cardiogenesis Corporation - Cardiogenesis Transmyocardial Laser. The device is indicated for use in the treatment of patients with angina (Canadian Cardiovascular Society Class 4) refractory to medical treatment and secondary to objectively demonstrated coronary artery atherosclerosis and with a region of the myocardium with reversible ischemia not amenable to direct coronary revascularization.
FDA Recall
Terminated
·Cardiogenesis Corporation·Product code MNO·May 1, 2011